NCT04173520

ELRIAH Score: A Simple Score for HCC Risk Stratification in CHC Patients With Cirrhosis or Advanced Liver Fibrosis Who Achieved SVR Following DAA Therapy

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 2,326 (actual)
• Sponsor: Egyptian Liver Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

aimed to develop a scoring system to assess risk of developing HCC in a large cohort of chronic hepatitis C (CHC) patients with advanced hepatic fibrosis (F3) or cirrhosis (F4) with sustained virological response (SVR) after receiving direct acting antivirals (DAAs).

Detailed description

Current guidelines recommend biannual surveillance for hepatocellular carcinoma (HCC) in all patients with cirrhosis. However, risk of HCC incidence is not the same for different patients. The study aimed to develop a scoring system to assess risk of developing HCC in a large cohort of chronic hepatitis C (CHC) patients with advanced hepatic fibrosis (F3) or cirrhosis (F4) with sustained virological response (SVR) after receiving direct acting antivirals (DAAs).

Conditions

• HCC

Interventions

Type	Name	Description
DRUG	DDA	Follow up after SVR

Timeline

• Start date: 2015-01-01
• Primary completion: 2019-08-01
• Completion: 2019-10-30
• First posted: 2019-11-22
• Last updated: 2019-11-26